The JAK2 V617F mutation is found in the majority of MPN patients including all three subtypes, such as in 95% of patients with polycythemia vera (PV) and 50–60% of patients with essential thrombocythemia (ET) or myelofibrosis (MF) (Table 1) [24]. Here, JAK2 is linked to acquired polycythemia vera.